Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy

Study Overview
=================
Brief Summary
-----------------
The study is an open label, non-randomized study designed to evaluate the diagnostic performance of SPECT CT.

Detailed Description
-----------------
The study is an open label, non-randomized study designed to evaluate the diagnostic performance of SPECT CT. The study will consist of 3 cohorts, and a subset of the patients in cohort C will participate in a test-retest study, where the baseline SPECT/CT will be repeated. SPECT CT will be performed in all cohorts. Cohort A will evaluate SPECT CT by comparison to a Positron Emission Tomography (PET) scan using NaF. Cohort B will evaluate SPECT CT by comparison to 18F-DCFPyL PET/CT. Cohort C will evaluate SPECT CT by comparison to Whole Body Magnetic Resonance Imaging (WB-MRI). Eligible subjects will be enrolled in a non-randomized manner per the treating physician discretion.

Official Title
-----------------
Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Procedure: SPECT CT
* Drug: 18F-DCFPyL PET/CT
* Drug: 18F-NaF PET/CT
* Procedure: WB-MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males ≥18 years of age. Subjects provide signed informed consent and confirm that they are able and willing to comply with all protocol requirements. Histologically confirmed adenocarcinoma of the prostate. Metastatic castration-resistant prostate cancer (mCRPC) with Bone metastases as manifested by one or more lesions on bone scan. Documented castrate level of serum testosterone (≤50 ng/dl). Documented progressive mCRPC based on at least one of the following criteria: PSA progression defined as 25% increase over baseline value or nadir. Radiographic progression for soft tissue lesions as per Response Evaluation Criteria in Solid Tumors (RECIST 1.1), and/ or radiographic progression for bone lesions as determined by radionuclide bone scan using the consensus guidelines of the PCWG3 criteria. Planning to receive first line novel hormonal therapy with Abiraterone or Enzalutamide for the first time for mCRPC within 4 weeks of documented progression. Baseline scans will be obtained prior to starting new therapy. Exclusion Criteria: Subjects who are unable to give valid informed consent Subjects who are unwilling or unable to undergo an SPECT, PET or MR exam, including subjects with contra-indications to MR exams. Subjects with prior Enzalutamide and Abiraterone for mCRPC Subjects with prior taxane chemotherapy for mCRPC Subjects administered any radioisotope within five physical half-lives or any IV X-ray contrast medium within 24 hours or any high density oral contrast medium (oral water contrast is acceptable) within 5 days prior to study drug injection. Subjects with any medical condition or other circumstances that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion. Patients with a history reaction to gadolinium contrast agent. For cohort C, patients with renal failure (eGFR < 60ml/min/1.73m2) or patients on dialysis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cohort A - SPECT CT and NaF PET<br>Intervention 1: SPECT CT Intervention 2: NaF PET | Procedure: SPECT CT<br>* MDP (99mTc-MDP) administration, about 180 min post-injection: whole body scan followed by a SPECT CT of regions designated by a board certified Nuclear Medicine physician after review of the whole body scan.<br>Drug: 18F-NaF PET/CT<br>* A dose of 5 mCi 18F-NaF is injected through the IV and followed by at least 10 ml of saline to flush the IV line of the remaining dose. At the 1 hour post injection time, total Whole Body Images take approximately 40 - 60 minutes depending on the height of the patient.<br>* Other names: NaF PET;|
| Experimental: Cohort B - SPECT CT and 18F-DCFPyL PET/CT<br>Intervention 1: SPECT CT Intervention 2: 18F-DCFPyL PET/CT | Procedure: SPECT CT<br>* MDP (99mTc-MDP) administration, about 180 min post-injection: whole body scan followed by a SPECT CT of regions designated by a board certified Nuclear Medicine physician after review of the whole body scan.<br>Drug: 18F-DCFPyL PET/CT<br>* A bolus of  9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.<br>* Other names: 18F-DCFPyL;|
| Experimental: Cohort C - SPECT CT and WB-MRI<br>Intervention 1: SPECT CT Intervention 2: WB-MRI | Procedure: SPECT CT<br>* MDP (99mTc-MDP) administration, about 180 min post-injection: whole body scan followed by a SPECT CT of regions designated by a board certified Nuclear Medicine physician after review of the whole body scan.<br>Procedure: WB-MRI<br>* Whole body MRI exam (total examination time < 50 minutes)<br>* Other names: Whole body MRI;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy for Prediction of Progression Free Survival as determined by Quantitative bone SPECT indices (QBSIs) | QBSI will be measured on SPECT scans at pre-defined intervals. A lower QBSI would mean likelier progression free survival. | Baseline, 3 months post-treatment, 6 months post-treatment, at time of disease progression assessed up to 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reproducibility of the QBSIs using test-retest studies in 12 patients | Reproducibility measured by difference in QBSI between test-retest in 12 patients, as defined by the protocol. A smaller difference in QBSI reflects greater reproducibility. | 5 years | 
| Ability of QBSPECT to detect recurrence of metastatic disease as determined by QBSI in 60 patients. | QBSI will be measured on QBSPECT images obtained at the same time as standard-of-care bone scans. A higher QBSI would predict earlier recurrence of metastasis. | Baseline, 3 months post-treatment, 6 months post-treatment, at time of disease progression assessed up to 5 years | 
| Accuracy of NaF PET/CT as determined by difference in QBSI from SPECT versus QBSI from NaF PET/CT in 20 patients | Difference in QBSI from SPECT versus NaF PET/CT. A smaller difference in the measured QBSI would reflect a higher accuracy of Na18F PET/CT. These images will be acquired within 32 hours of the bone scintigraphy scans at the pre-defined time points, per protocol. | Baseline, 3 months post-treatment, 6 months post-treatment, at time of disease progression assessed up to 5 years | 
| Accuracy of PSMA PET/CT as determined by difference in QBSI from SPECT versus QBSI from PSMA PET/CT in 20 patients | Difference in QBSI from SPECT versus PSMA PET/CT. A smaller difference in the measured QBSI would reflect a higher accuracy of PSMA PET/CT. These images will be acquired within 32 hours of the bone scintigraphy scans at the pre-defined time points, per protocol. | Baseline, 6 months post-treatment, assessed up to 5 years | 
| Correlation of QBSI from SPECT/CT to restricted diffusion obtained from whole body MRI | Ratio of QBSI obtained from SPECT imaging to quantitative biomarkers of restricted diffusion (diffusion-weighted imaging) obtained from a WB-MRI protocol. | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
J1835, SPECT CT, PSMA, 18F-DCFPyL PET/CT, WB-MRI, NaF